The efficacy of pro- and anticoagulant therapy in plasma from patients with liver cirrhosis .

The efficacy of pro- and anticoagulant therapy in plasma from patients with liver cirrhosis . - EPAC

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON37417

Enrollment

126

Registered

2012-06-06

Start date

2012-08-06

Completion date

Unknown

Last updated

2024-04-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

coagulation. hemostasis

Interventions

None listed

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria study group: - Cirrhosis - >18 year - Signed informed consent Inclusion criteria healhty control group - >18 year - Signed informed consent

Exclusion criteria

Exclusion criteria: Exclusion criteria study group: - Congenital coagulation disorder - Active infection - Acute liver failure - Use of anticoagulant drugs in the past 10 days - Pregnancy - HIV+ - (2 weeks) - Use of anticoagulant drugs in the past 10 days - Pregnancy

Design outcomes

Primary

Measure	Time frame
The functionality of the secondary hemostatic system, as determined by thrombin generation assays.	—

Countries

Netherlands

Outcome results